Status:
COMPLETED
First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187
Lead Sponsor:
Galapagos NV
Conditions:
Healthy
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) subcutaneous and single oral dose of GLPG0187 compared to placebo. Also, pharmacokinetics (PK) and pharma...
Eligibility Criteria
Inclusion
- healthy male, age 18-50 years
- BMI between 18-30 kg/m², inclusive
Exclusion
- significantly abnormal platelet function or coagulopathy
- smoking
- drug or alcohol abuse
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00928343
Start Date
June 1 2009
End Date
December 1 2009
Last Update
January 15 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SGS Stuivenberg
Antwerp, Belgium